LibraGen to find new path to active for Pierre Fabre Medicament R&D
LibraGen, a French bacterial process and discovery specialist, has signed an agreement with the R&D department of Pierre Fabre Medicament, France's second largest independent pharmaceutical company. Under the agreement, LibraGen will use enzymatic technologies to optimise the synthesis of an active ingredient of one of Pierre Fabre's medicines.
LibraGen, a French bacterial process and discovery specialist, has signed an agreement with the R&D department of Pierre Fabre Medicament, France's second largest independent pharmaceutical company. Under the agreement, LibraGen will use enzymatic technologies to optimise the synthesis of an active ingredient of one of Pierre Fabre's medicines.
This enzymatic production process would bypass the need for several stages of chemical synthesis, thus optimising production costs and significantly improving environmental impact.
'Biocatalysis is a tool which is revolutionising chemical production processes in the pharmaceutical field,' said Renaud Nalin, LibraGen's ceo. 'This agreement demonstrates the level of maturity and expertise now attained by LibraGen in the field of bio-catalysis, and also reflects our strategic commitment to the forging of partnerships with the pharma industry.'